Brigham and Women’s study finds rapid increase in the use of brachytherapy for breast cancer radiotherapy:

Brigham and Women’s study finds rapid increase in the use of brachytherapy for breast cancer radiotherapy:   NCI Cancer Center News Accelerated partial breast irradiation using brachytherapy (APBIb) for the treatment of breast cancer has been rapidly increasing over the last several years in the U.S. as an alternative to standard whole-breast irradiation (WBI), according … Continue reading “Brigham and Women’s study finds rapid increase in the use of brachytherapy for breast cancer radiotherapy:”

Brigham and Women’s study finds rapid increase in the use of brachytherapy for breast cancer radiotherapy:

 

NCI Cancer Center News

Accelerated partial breast irradiation using brachytherapy (APBIb) for the treatment of breast cancer has been rapidly increasing over the last several years in the U.S. as an alternative to standard whole-breast irradiation (WBI), according to a study published December 16th in the Journal of the National Cancer Institute. Because of the growing popularity of APBIb in particular, researchers at the Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues performed a retrospective analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database of women who had received either APBIb or WBI between 2000 and 2007.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply